Adolescent care pathways: scope of practice across psychology, psychiatry, and testing

Referral patterns for adolescent mental-health care vary substantially by region, payer mix, and the scope-of-practice education clinicians received during training. This reference is intended for clinicians, trainees, and advanced-practice providers who routinely handle the front-line referral question for adolescents and their families: who does what, and when?

Scope of practice — a structured comparison

| | Master’s clinicians (LMFT/LCSW/LPC/MFT) | Psychologist (PsyD/PhD) | Psychiatrist (MD/DO) | PMHNP / NP | |---|---|---|---|---| | Diagnostic | Provisional clinical | Yes — including formal testing | Yes — full DSM-5-TR | Yes | | Prescribes | No | No (except 5 US states + military) | Yes — full pediatric formulary | Yes (with state and supervision variation) | | Psychological testing | No | Yes | No (refers to psychology) | No | | Modalities typically delivered | CBT, DBT, IPT-A, family therapy, EMDR, MI | CBT, DBT, ACT, exposure work, neuropsych testing, supervision | Medication management; some integrated therapy practices | Medication management; some therapy | | Typical session structure | Weekly 45–50 min | Weekly 45–50 min therapy or testing battery sessions | 60–90 min initial; 20–30 min med-management follow-up | Same as psychiatry | | Adolescent-specific training | Variable; check program | Pediatric internship / fellowship if specialty | Required two-year child & adolescent psychiatry fellowship for board-certified CAP | Pediatric PMHNP track when available |

The most actionable takeaways:

• For most adolescent presentations, the master’s-level clinician delivering evidence-based therapy is the appropriate primary therapeutic provider.
• Psychological testing is a distinct service from psychotherapy; not all psychologists offer it, and not all situations require it.
• For prescribing in adolescents, the difference between a board-certified child and adolescent psychiatrist and a general adult psychiatrist is clinically meaningful, particularly for SSRI initiation, mood-disorder differential, and stimulant management.

Indications for psychological testing in adolescents

Per AACAP and AAP guidance, psychological or neuropsychological testing in adolescents is indicated for:

1. Diagnostic uncertainty after standard clinical evaluation, particularly when ruling in or out comorbid neurodevelopmental conditions.
2. Suspected learning disorder — specific learning disorder in reading, mathematics, or written expression — particularly when academic underperformance is unexplained by clinical interview.
3. Suspected autism spectrum disorder requiring formal assessment for diagnosis, intervention planning, or service eligibility.
4. Twice-exceptional presentations — high cognitive ability with specific learning or attention disorders — where clinical interview is insufficient to characterize the strengths-and-deficits profile.
5. Traumatic brain injury assessment and post-injury baseline.
6. Eligibility documentation for school accommodations under IDEA, Section 504, or college-level disability services.
7. Pre-surgical or pre-treatment evaluation for specific medical contexts (transplant, bariatric, gender-affirming care).

Routine ADHD diagnosis does not require neuropsychological testing per the AAP 2019 guideline. A clinical evaluation incorporating standardized rating scales (Vanderbilt, Conners) across multiple settings is sufficient. Testing for ADHD is appropriate when the diagnosis is unclear, when comorbid learning disorders are suspected, or when standard treatment has not produced expected response.

First-line evidence summary by diagnosis

Adolescent depression (MDD)

• Mild to moderate: CBT or IPT-A monotherapy is first-line. SSRI monotherapy is an alternative.
• Moderate to severe: Combination CBT + SSRI per TADS (fluoxetine preferred for first-line based on adolescent evidence base).
• Treatment-resistant: TORDIA-informed approach — switch SSRI plus add CBT.
• Cipriani 2016 network meta-analysis: fluoxetine alone among antidepressants showed clear benefit-over-risk profile in pediatric MDD.

Adolescent anxiety disorders

• Mild to moderate: CBT monotherapy is first-line, per CAMS and consistent meta-analytic evidence.
• Moderate to severe: Combination CBT + SSRI (sertraline used in CAMS; fluoxetine and escitalopram are also first-line).
• Specific subtypes: exposure therapy is the active component for specific phobia, social anxiety, and panic; ERP for OCD.

Adolescent OCD

• Mild to moderate: Exposure and response prevention (ERP) monotherapy.
• Moderate to severe: Combination ERP + SSRI per POTS (sertraline used in trial; fluvoxamine, fluoxetine also first-line).
• Treatment-resistant: SSRI augmentation with low-dose atypical antipsychotic or clomipramine, with specialty involvement.

Adolescent ADHD

• First-line: Methylphenidate or amphetamine stimulant monotherapy per AAP guideline. Behavioral interventions are recommended adjunctively.
• Stimulant-intolerant or non-responder: Atomoxetine, guanfacine ER, clonidine ER. The MTA study supports combination behavioral and pharmacological treatment for optimized functional outcomes.

Adolescent bipolar disorder

• Acute mania: Atypical antipsychotic monotherapy is first-line; lithium and valproate are second-line in adolescents.
• Maintenance: Lithium has the strongest pediatric evidence; atypicals are commonly used.
• Bipolar depression: lurasidone has FDA pediatric indication; treatment of bipolar depression in adolescents requires specialty-level care due to switch risk with antidepressant monotherapy.

Adolescent eating disorders

• Anorexia nervosa: Family-based treatment (FBT, Maudsley method) is first-line for medically stable adolescents.
• Bulimia nervosa: CBT-E or family-based treatment for adolescents; fluoxetine has FDA approval as adjunct.
• Medical instability: Refeeding-protocol inpatient or partial hospitalization; SSRIs not effective in malnourished anorexia.

The three-tier care model in routine practice

In typical outpatient practice, adolescent care organizes into three tiers:

Tier 1 — Primary care plus therapy. Most adolescent presentations are appropriately managed by a pediatrician or family medicine physician prescribing first-line medication when indicated, in coordination with a master’s-level therapist delivering evidence-based therapy. This is the intended steady state for most uncomplicated cases.

Tier 2 — Specialty psychiatric care plus therapy. Indications include treatment-resistance, diagnostic complexity, comorbid presentations, medication outside primary-care comfort, or family preference. The structure remains therapy-plus-medication; the prescribing handoff moves from pediatrician to psychiatrist.

Tier 3 — Higher level of care. Intensive outpatient (IOP), partial hospitalization (PHP), residential, or inpatient. Indications include safety concerns, medical instability, or treatment failure at lower intensity.

Specialist-level referral indications

Beyond the routine therapy-plus-prescriber model, indications for explicit specialty involvement:

• Adolescent psychiatry: moderate-to-severe MDD with suicidality, suspected bipolar, treatment-resistant anxiety or depression, complex comorbidity, prescribing of agents outside primary-care scope.
• Pediatric psychology with testing expertise: comprehensive diagnostic evaluation, learning disorder assessment, ASD assessment, complex developmental presentations.
• Pediatric subspecialty consultation: developmental-behavioral pediatrics for early-onset autism or developmental disabilities; pediatric neurology for tic disorders, seizure-related psychiatric symptoms; adolescent medicine for eating-disorder medical management.

Practice considerations

Insurance and prior authorization. Stimulants typically clear without prior auth; atomoxetine and second-generation antipsychotics often require PA. SSRIs vary by formulary. Therapy authorization typically straightforward for established CPT codes (90791, 90834, 90837); psychological testing authorization (96130–96139) often requires specific medical necessity documentation.

Telehealth. Adolescent psychiatry and therapy are well-supported via telehealth post-2020. Initial evaluations are increasingly hybrid (initial in-person, follow-ups remote). State licensure for cross-state telehealth remains variable and worth verifying.

Documentation considerations. For any pediatric prescribing, documentation of: differential diagnosis, informed consent including black-box discussion for SSRIs, baseline rating scales, monitoring plan, collateral information sources, coordination-of-care releases. For testing referrals, document specific diagnostic question and prior workup.

Quick reference

| Presentation | First-line modality | First-line agent | Specialty referral threshold | |---|---|---|---| | Mild-moderate anxiety | CBT | — | CBT non-response at 16 weeks | | Moderate-severe anxiety | CBT + SSRI | Sertraline / fluoxetine / escitalopram | Inadequate response or complex comorbidity | | Mild-moderate depression | CBT or IPT-A | — | Symptom worsening or suicidality | | Moderate-severe depression | CBT + SSRI | Fluoxetine | Suicidality, bipolar concern, treatment-resistance | | OCD | ERP | Sertraline / fluoxetine / fluvoxamine | Functional impairment, partial response | | ADHD | Stimulant + behavioral | Methylphenidate or amphetamine | Comorbidity, two-medication failure | | Bipolar disorder | Mood stabilizer or atypical | Lithium / lurasidone | Always specialty | | Anorexia nervosa | FBT | — (most antidepressants ineffective in malnourished state) | Medical instability, FBT failure |

The short version

For most adolescent presentations, the appropriate care structure is a master’s-level therapist delivering evidence-based therapy with a pediatrician or specialist prescribing when indicated. Specialty psychiatric involvement is genuinely indicated in roughly the situations above: moderate-to-severe mood and anxiety, OCD with impairment, complex comorbidity, suspected bipolar, treatment-resistance, or prescribing outside primary-care comfort. Combination treatment (therapy plus medication) outperforms monotherapy for moderate-to-severe presentations across the major diagnoses.